Potential of mRNA vaccines to become versatile cancer vaccines

doi:10.5306/wjco.v13.i8.663

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4393)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

278

WORD

HTML

2373

Figures (1-1)

178

Tables (1-1)

190

Sum=3062

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

185

Download

447

Sum=632

Publishing Process of This Article

Item

Count

Browse

246

Download

453

Sum=699

Aug 24, 2022 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Field of Vision

World J Clin Oncol. Aug 24, 2022; 13(8): 663-674
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.663

Open in New Tab Full Size Figure Download Figure

Figure 1 Selected combinations with cancer treatment vaccines: Immune checkpoint inhibitors, radiotherapy, metronomic chemotherapy, and metformin. ^aEspecially mRNA cancer vaccines: cell-free, rapid production, versatile and inherent adjuvant properties outperforming pathogen vaccines repurposed for oncology. Even balancing innate and adaptive immunities is feasible with mRNA. ^bMetformin’s long standing safety track record, ready availability and eminent affordability may enable an ideal combination with mRNA cancer vaccines. ICI: Immune checkpoint inhibitors; mChT: Metronomic chemotherapy; RT: Radiotherapy.

Citation: Tsao SY. Potential of mRNA vaccines to become versatile cancer vaccines . World J Clin Oncol 2022; 13(8): 663-674
URL: https://www.wjgnet.com/2218-4333/full/v13/i8/663.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i8.663